Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? - Jazz Pharmaceuticals ( NASDAQ:JAZZ )

a week ago

Jazz Pharmaceuticals plc JAZZ reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze. The gross margin held steady at 89%.

Ticker	Sentiment	Impact
JAZZ	Bullish	44 %